SS-20

What is SS-20?

SS-20 (Szeto-Schiller peptide 20) is a mitochondria-targeting tetrapeptide with the sequence Phe-D-Arg-Phe-Lys-NH2. It was developed in the laboratory of Hazel Szeto and Peter Schiller at Cornell as part of the broader Szeto-Schiller (SS) peptide series — the same research lineage that produced SS-31 (elamipretide / FORZINITY), the first FDA-approved mitochondrial peptide therapeutic.

SS-20 is research-only and not in active clinical development. It is increasingly mentioned in mitochondrial biohacker communities and longevity research because of its relationship to elamipretide and its specific cardiolipin-targeting properties.

Structure

SS peptides share a defining structural feature: an alternating aromatic-cationic motif that allows them to:

1. Selectively concentrate in the mitochondrial inner membrane (~1000-fold higher than cytoplasm)
2. Bind cardiolipin, the unique mitochondrial inner-membrane phospholipid
3. Stabilize the local lipid environment around respiratory chain complexes

Sequences:

• SS-31 (elamipretide): D-Arg-Dmt-Lys-Phe-NH2 (where Dmt = 2,6-dimethyltyrosine)
• SS-20: Phe-D-Arg-Phe-Lys-NH2

The substitution of Dmt (in SS-31) with Phe (in SS-20) eliminates the antioxidant tyrosyl radical chemistry, producing a peptide with the same cardiolipin-binding/membrane-stabilizing activity but no direct ROS scavenging.

Mechanism of Action

• Cardiolipin binding — concentrates at the inner mitochondrial membrane
• Cristae stabilization — preserves cristae structure under stress
• Respiratory chain organization — supports supercomplex assembly and electron transport efficiency
• Increased ATP production — observed in dysfunctional mitochondria
• No direct ROS scavenging — distinguishes SS-20 from SS-31

The mechanism distinction matters: SS-31's clinical effects in heart failure and other indications were originally hypothesized to depend on its antioxidant activity, but SS-20 produces similar bioenergetic improvements without the antioxidant chemistry — supporting the hypothesis that cardiolipin binding and cristae stabilization, not antioxidant activity, drives the therapeutic effect.

Research Evidence

SS-20 has been studied in:

• Cardiac ischemia-reperfusion injury models — protective effect comparable to SS-31
• Heart failure models — improved cardiac function
• Aging-related mitochondrial dysfunction in skeletal muscle and brain
• Diabetic complications

These are predominantly cellular and animal studies. No clinical trials of SS-20 have been registered.

Place in Research

SS-20 is used in academic mitochondrial research as:

• A mechanistic control for SS-31 — distinguishing antioxidant from cardiolipin-binding effects
• A structure-activity probe for the SS peptide family
• A potential alternative therapeutic agent for indications where direct ROS scavenging may be undesirable

Availability

SS-20 is sold by several research chemical suppliers for laboratory use. It has no approved clinical use; human safety data are limited to small early-phase studies in oncology contexts (where the related SS peptides have been studied).

Distinction from SS-31 / Elamipretide

SS-20's primary value as of 2026 is in mitochondrial mechanism research; it is unlikely to enter clinical development as a separate therapeutic given the regulatory advancement of SS-31/elamipretide.